Judith Trotman | EHA 2018 | Key findings from the INNOVATE study

By Elina Simanovits, Judith Trotman

Featured

Judith Trotman

Jun 18, 2018

23rd Congress of the European Hematology Association, 14-17 June 2018, Stockholm, Sweden
Judith Trotman
Concord Repatriation General Hospital, Sydney, AU

Interview topic: Key findings from the INNOVATE study

Judith Trotman | EHA 2018 | Key findings from the INNOVATE study

More about...

EHA 2018 Ibrutinib Indolent B-cell lymphomas iNNOVATE Rituximab Waldenström’s macroglobulinemia

EHA 2018 | Results from the phase III trial of ibrutinib/rituximab versus placebo/rituximab in WM

Jul 19, 2018

EHA 2018 | Results from the phase III trial of ibrutinib/rituximab versus placebo/rituximab in WM

Jul 19, 2018

Prof. Judith Trotman | ASH 2017 | BRIGHT study results

Professor Judith Trotman Interview Topic: Based on the BRIGHT study results, would you consider maintenance rituximab after BR the standard of care for FL patients?

Jan 3, 2018

Prof. Judith Trotman | ASH 2017 | BRIGHT study results

Professor Judith Trotman Interview Topic: Based on the BRIGHT study results, would you consider maintenance rituximab after BR the standard of...

Jan 3, 2018

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Judith Trotman | EHA 2018 | Key findings from the INNOVATE study

By Elina Simanovits, Judith Trotman

Featured

Judith Trotman

Jun 18, 2018

More about...

Related articles

Jul 19, 2018

Jul 19, 2018

Jan 3, 2018

Jan 3, 2018

Newsletter